Kraft Heinz (KHC) Receives a Hold from TD Cowen
TD Cowen analyst Robert Moskow maintained a Hold rating on Kraft Heinz (KHC – Research Report) today and set a price target of $27.00. The company's shares closed yesterday at $27.90.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Moskow is a 3-star analyst with an average return of 2.1% and a 46.09% success rate. Moskow covers the Consumer Defensive sector, focusing on stocks such as Mondelez International, Vital Farms, and McCormick & Company.
In addition to TD Cowen, Kraft Heinz also received a Hold from Barclays's Andrew Lazar in a report issued today. However, on the same day, Morgan Stanley maintained a Sell rating on Kraft Heinz (NASDAQ: KHC).
Based on Kraft Heinz's latest earnings release for the quarter ending March 29, the company reported a quarterly revenue of $6 billion and a net profit of $712 million. In comparison, last year the company earned a revenue of $6.41 billion and had a net profit of $801 million
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
12 minutes ago
- Globe and Mail
A surprising answer to the question: Which big bank has the best mobile app?
The basics of a good mobile banking app are seamless and speedy log-in, modern appearance and easy navigation. According to a new J.D. Power customer satisfaction survey, the Big Five banks all deliver on these points. 'It's getting harder to tell the nation's banks and credit card company mobile apps and websites apart from one another,' the survey concludes. Do Canadian banks have a homogeneity problem? Their earnings and stock market performance certainly differ, but there's a sameness to the customer experience once you get beyond logos and colour schemes. App parity reflects this, but so other aspects of consumer banking. Does any bank do chequing, mortgages or investments demonstrably better than the rest? Canadian Imperial Bank of Commerce took top spot in banking app satisfaction with a score of 641 out of 1,000, Toronto-Dominion Bank scored 631, Bank of Montreal and Royal Bank of Canada 626 and Bank of Nova Scotia 620. On credit-card apps, American Express led a larger field of competitors with a score of 692 and Tangerine was second at 669. After that, most competitors were bunched in the mid- to low-600 range. J.D. Power says banks have spent years maximizing the functionality of their apps within the limits of their current technology. The next frontier will be adding AI-based functions, which clients are encountering more in other aspects of their lives. I use a few alternative bank apps and haven't yet found any that crush the competition. But as we look ahead to open banking, let's not concede that all apps will be more or less the same. Open banking will allow bank clients to securely share financial data with alternative players. Let's see whether they can use it to build a better app. A surprising finding in the J.D. Power customer satisfaction numbers is that people like multi-factor authentication when logging into a mobile app. MFA can be a hassle if you're in a hurry. For example, you may be asked for a verification code sent to by your bank via text, or to use a fingerprint reader. Still, J.D. Power said overall customer satisfaction is 12 points higher when customers use multi-factor authentication before logging in. This shift reflects improvements banks have made in the usability of MFA, and an increased focus on security by bank customers. Are you reading this newsletter on the web or did someone forward the e-mail version to you? If so, you can sign up for Carrick on Money here. Housing affordability: Canada vs. the U.S. Vancouver, Toronto and Victoria top this ranking of North American cities by housing affordability – specifically, mortgage payment as a percentage of income. The list highlights just how much cheaper homes are in the U.S., even in big cities like New York. Top choices for simple and great investing An investing blogger sorts through some of the biggest asset allocation exchange-traded funds and identifies some top choices. Asset-allocation ETFs are a simple, cheap and excellent way to build a fully diversified portfolio of exchange-traded funds. Personal finance's independence movement Christine Benz, director of personal finance and retirement for the investing analysis company Morningstar, recently attended an event held for people who follow the F.I.R.E. philosophy – financial independence, retire early. She picked up a few lessons to pass along on balancing work and the powerful idea of financial freedom. Bet you lose Toronto Life on the betting scandal involving a former Toronto Raptor. What I took away from this story is a sense of shock about the amount being wasted on ridiculous sports betting. The player in question was a day trader, and a gambler. Subscribe to Stress Test on Apple podcasts or Spotify. Q: If we are going to experience rough seas for the next two to four years, I want to be on the largest warship in the fleet. That would be U.S. equities. Is that approach reasonable? A: As dominant as the U.S. stock market has been in the past decade, strong returns from Canadian stocks lately mean the five-year annualized total return of the S&P/TSX composite index is now more or less even with the S&P 500. Meanwhile, international stocks have been coming on strong. The U.S. market offers exposure to leading companies in tech, health care and consumer discretionary stocks, but investors are looking at other markets these days. Do you have a question for me? Send it my way. Sorry I can't answer every one personally. Questions and answers are edited for length and clarity. Tools and guides A beginner's guide to guaranteed investment certificates. In the social sphere Social Media: How often do people upgrade their smartphone? Watch: Thoughts on the worries involved in home ownership. Not buying so much, but living up to the responsibilities of owning a property. Money-Free Zone: Paul Weller has to be one of the most eclectic and versatile musicians around. He's been a new-wave rocker, a neo-soul musician and, more recently, a singer-songwriter who puts out nuggets like this new cover of a 1974 song called Pinball by singer-actor Brian Protheroe. You can catch Weller at his new wave peak in That's Entertainment, an all-time great song. Weller's soul-era band was called The Style Council – here's one of their most enjoyable songs, The Big Boss Groove. More PF from The Globe - Five tax tips for cottage owners this summer season - The best time to make a lump-sum mortgage payment, according to the experts - Canadians go elbows up on U.S. travel, opting for these destinations instead - Trump-proofing your wallet
Globe and Mail
15 minutes ago
- Globe and Mail
Strategy (MSTR) Buys Another $110 Million of Bitcoin
Strategy (MSTR) continues to purchase Bitcoin (BTC) even as the price rises. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter In the past week, the software company turned serial Bitcoin acquirer bought an additional 1,045 BTC for $110.2 million. The company, led by founder Michael Saylor, paid an average purchase price of $105,426 each for its latest Bitcoin accumulation. Strategy, formerly known as MicroStrategy, now owns 582,000 Bitcoin worth $62.5 billion. The company is the largest corporate owner of BTC in the world. Strategy's average purchase price for its Bitcoin holdings is $70,086 per digital token. Funding Purchases Last week's buys were funded via at-the-market sales of Strategy's preferred stock, according to a regulatory filing with the U.S. Securities and Exchange Commission (SEC). The company remains committed to its focus on aggressively acquiring Bitcoin. Strategy's stock has risen 25% this year to trade at $374.47 per share. The price of Bitcoin is currently right around $107,500, having gained 12% on the year. Is BTC a Buy? Most Wall Street firms don't offer ratings or price targets on Bitcoin, so we'll look instead at its three-month performance. As one can see in the chart below, the price of BTC has risen 34.14% in the last 12 weeks.
Globe and Mail
15 minutes ago
- Globe and Mail
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
AbbVie ABBV expects to return to robust revenue growth in 2025, just two years after losing U.S. exclusivity for its flagship drug, Humira. The drug, which went off-patent in January 2023, saw first-quarter 2025 sales decline nearly 50% year over year to $1.12 billion. Humira had already lost exclusivity in ex-U.S. markets in 2018. Despite the steep decline, ABBV's ex-Humira platform grew more than 21% year over year (on a reported basis) in the first quarter of 2025, driven by its newer immunology drugs, Skyrizi and Rinvoq. The company successfully launched Skyrizi and Rinvoq across Humira's major indications and a distinct new indication, atopic dermatitis. Both drugs showed strong performance across all approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes two conditions: ulcerative colitis (UC) and Crohn's disease (CD). Strong immunology-market growth, market share gains and momentum from new indications, such as the recent launch of Skyrizi in UC, as well as the potential for five new indications for Rinvoq over the next few years, are expected to drive these drugs' future growth. On the back of this continued momentum, AbbVie raised its previously issued guidance by around $900 million and now expects to record $24.7 billion from the combined sales of both drugs this year. Our model estimates the combined sales figure to be around $24.85 billion. ABBV's Competition in the Immunology Space The targeted market is highly competitive. A key player in this area is Johnson & Johnson JNJ, which already markets blockbuster medications, Stelara and Tremfya. Both of these J&J drugs are approved across multiple immunology indications, including UC and CD indications. Since Stelara lost U.S. LoE earlier this year, J&J has shifted focus to Tremfya to maintain its foothold in the immunology space. Another pharma giant expanding its presence in immunology is Eli Lilly LLY, following the FDA approval of Omvoh for the UC indication in late 2023. Omvoh marked Lilly's first immunology drug approved for a type of IBD in the United States and plays a key role in building out its immunology portfolio. This Lilly drug received FDA approval for the CD indication in January. ABBV's Price Performance, Valuation and Estimates Shares of AbbVie have outperformed the industry year to date, as seen in the chart below. From a valuation standpoint, AbbVie is not very cheap. Based on the price/earnings (P/E) ratio, the company's shares currently trade at 14.48 times forward earnings, a tad lower than its industry's average of 15.12. The stock is cheaper than some other large drugmakers, such as Eli Lilly and Novo Nordisk but is priced much higher than most other large drugmakers. The stock is also trading above its five-year mean of 12.38. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has declined from $12.30 per share to $12.28, while that for 2026 has increased from $13.97 to $14.05 over the past 60 days. AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report
